CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...